Iodixanol pegolAlternative Names: Iodixanol pegol nanoparticles - Marval Pharma; NCTX; PEGylated liposomal iodixanol injection - Marval Pharma
Latest Information Update: 21 Apr 2016
At a glance
- Originator Marval Pharma
- Class Contrast media; Polyethylene glycols; Triiodobenzoic acids
- Mechanism of Action Emission-computed tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Cancer; Cardiovascular disorders
Most Recent Events
- 09 Oct 2014 Marval Pharma terminates a phase I trial in Healthy volunteers in USA (NCT02063594)
- 06 Mar 2014 Phase-I clinical trials in Cancer and Cardiovascular disorders and Atherosclerosis (diagnosis; in volunteers) in USA (IV) (NCT02063594)